Get the Stockscreener App
1.25
3.85%
-0.05
After Hours:
1.28
0.03
+2.40%
Dermata Therapeutics Inc stock is traded at $1.25, with a volume of 98,802.
It is down -3.85% in the last 24 hours and up +5.04% over the past month.
Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.
See More
Previous Close:
$1.30
Open:
$1.32
24h Volume:
98,802
Relative Volume:
0.05
Market Cap:
$5.03M
Revenue:
-
Net Income/Loss:
$-7.56M
P/E Ratio:
-0.237
EPS:
-5.274
Net Cash Flow:
$-7.76M
1W Performance:
-7.41%
1M Performance:
+5.04%
6M Performance:
-70.31%
1Y Performance:
-84.56%
1-Day Range:
$1.24
$1.333
1-Week Range:
$1.20
$1.40
52-Week Range:
$1.10
$9.899
Dermata Therapeutics Inc Stock (DRMA) Company Profile
Name
Dermata Therapeutics Inc
Sector
Industry
Phone
(858)-223-0882
Address
3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO
Compare DRMA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRMA
Dermata Therapeutics Inc
|
1.25 | 4.91M | 0 | -7.56M | -7.76M | -5.274 |
VRTX
Vertex Pharmaceuticals Inc
|
444.28 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
755.51 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
828.35 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
339.41 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
310.00 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Dermata Therapeutics Inc Stock (DRMA) Latest News
Patterns Watch: Does LogProstyle Inc have strong fundamentalsDip Buying & Expert Approved Momentum Ideas - baoquankhu1.vn
Sentiment Watch: Will Dermata Therapeutics Inc Equity Warrant outperform the market in YEARWeekly Trade Analysis & High Accuracy Swing Trade Signals - baoquankhu1.vn
WSBCO Should I Buy - Intellectia AI
Bond Watch: Is Dermata Therapeutics Inc Equity Warrant stock risky to hold nowRate Cut & Precise Swing Trade Alerts - baoquankhu1.vn
Moving Averages: Is Dermata Therapeutics Inc Equity Warrant gaining market share2026 Institutional & Verified Technical Signals - baoquankhu1.vn
Dermata Therapeutics Inc. (DRMA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Market Review: Will Dermata Therapeutics Inc benefit from AI trendsEntry Point & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Aug Sectors: Is Dermata Therapeutics Inc Equity Warrant benefiting from innovation trendsTrade Exit Report & Weekly Top Gainers Trade List - baoquankhu1.vn
Targets Report: Is Dermata Therapeutics Inc Equity Warrant stock undervalued right nowWeekly Stock Report & Daily Volume Surge Signals - baoquankhu1.vn
Gap Down: Will Bukit Jalil Global Acquisition 1 Ltd Equity Warrant benefit from green energy policies2026 Trends & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
Analyst Calls: Whats the outlook for Dermata Therapeutics Incs sector2026 Price Targets & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
[PRE 14A] Dermata Therapeutics, Inc. Preliminary Proxy Statement - Stock Titan
Take Profit: Is Dermata Therapeutics Inc Equity Warrant benefiting from innovation trendsQuarterly Risk Review & Reliable Intraday Trade Plans - baoquankhu1.vn
Market Moves: Can Dermata Therapeutics Inc Equity Warrant weather a recessionRate Hike & Smart Investment Allocation Insights - baoquankhu1.vn
ALYAF Should I Buy - Intellectia AI
DRMA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Plus Therapeutics Inc (XMP0.DU) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Dermata shares rise after USPTO issues patent notice of allowance - MSN
DRMA Should I Buy - Intellectia AI
Dermata receives Australian patent acceptance for topical filler - Investing.com Australia
Dermata Therapeutics Receives Australian Patent Acceptance for Bioneedle Dermal Filler Delivery System - geneonline.com
Dermata receives Australian patent acceptance for topical filler By Investing.com - Investing.com Canada
Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System - The Batesville Daily Guard
Dermata clears Australian patent hurdle for topical dermal fillers - Stock Titan
Maxim Group Maintains Dermata Therapeutics(DRMA.US) With Buy Rating, Cuts Target Price to $4 - Moomoo
Guidance Update: Will Dermata Therapeutics Inc Equity Warrant benefit from AI trendsMarket Sentiment Report & Verified Short-Term Plans - baoquankhu1.vn
Tangible book value per share of Dermata Therapeutics, Inc. – NASDAQ:DRMAW - TradingView
Total debt per share of Dermata Therapeutics, Inc. – NASDAQ:DRMAW - TradingView — Track All Markets
Aug Levels: Will Dermata Therapeutics Inc benefit from seasonality2026 Summary & Stepwise Trade Signal Guides - baoquankhu1.vn
Quarterly Trades: Is Dermata Therapeutics Inc stock forming a cup and handleQuarterly Portfolio Review & Weekly Watchlist of Top Performers - baoquankhu1.vn
Dermata Therapeutics Reports Increased Losses in FY Earnings - Intellectia AI
Dermata Therapeutics 2025 Financial Update - AlphaStreet
Dermata Therapeutics Inc stock rises amid market gains - Intellectia AI
Southland Holdings, Inc. (SLND) Reports Wider Q4 Loss Than Expected - news.alphastreet.com
Dermata Therapeutics Announces Strategic Pivot to DTC Skincare with Tome Brand and Plans 2026 Product Launch - Minichart
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025 - Bitget
Dermata Therapeutics 10-K: $7.56M net loss, operating expenses $7.77M - TradingView
Dermata Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Dermata Therapeutics (NASDAQ: DRMA) pivots from Rx acne to Tome OTC skincare - Stock Titan
Dermata (NASDAQ: DRMA) shifts to DTC skincare as 2025 loss shrinks - Stock Titan
Analyst Downgrade: Will Dermata Therapeutics Inc benefit from AI trendsLong Setup & Precise Swing Trade Alerts - baoquankhu1.vn
Dermata Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Risk Recap: Is Dermata Therapeutics Inc Equity Warrant a strong candidate for buy and hold2026 Top Decliners & Comprehensive Market Scan Reports - baoquankhu1.vn
Fennec Pharmaceuticals Inc. (FENC) Misses Q4 EPS Estimates - news.alphastreet.com
If You Invested $1,000 in Protagenic Therapeutics Inc (PTIX) - Stock Titan
If You Invested $1,000 in THERIVA BIOLOGICS INC (TOVX) - Stock Titan
Valuation Update: Is Dermata Therapeutics Inc. Equity Warrant stock risky to hold now2026 Summary & Safe Entry Point Identification - baoquankhu1.vn
Dermata Therapeutics Poised for Expansion with Strategic Skincare Launch - timothysykes.com
Dermata Therapeutics Strategically Pivots with New Skincare Launch - StocksToTrade
Dermata Therapeutics Strategically Expands into Skincare with Executive Appointment - timothysykes.com
Why Planet Labs Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket - Sahm
Dermata Therapeutics Inc Stock (DRMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):